The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Abridge aligns with Eli Lilly and Nvidia to push an AI “scribe” into clinical conversations
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 12, 12:41 PM EDT

Abridge aligns with Eli Lilly and Nvidia to push an AI “scribe” into clinical conversations

Abridge said it is pairing its documentation-focused AI with Nvidia’s AI infrastructure and has drawn a strategic investment from Eli Lilly, aiming to expand capabilities for how clinicians capture and review patient conversations.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Abridge, a company known for AI that helps generate clinical notes, said it is working with Nvidia to build a foundation model designed for clinical conversations, and it announced a strategic investment from drugmaker Eli Lilly. The announcements were made during a keynote described in a report carried by Yahoo Finance.

In its description of the plan, Abridge framed the work as an effort to move beyond basic transcription into a model that can handle the context and content of patient-clinician conversations, a step that could make documentation more useful during care and review after the visit.

Abridge’s approach centers on an “AI scribe” concept, which generally refers to software that assists clinicians by turning recorded or observed interactions into draft documentation. The company’s stated goal, as described in the report, is to expand that capability by using a larger, more general “foundation model” that can be adapted to specific clinical conversation tasks.

Eli Lilly’s involvement was characterized in the report as a strategic investment rather than a reported commercial contract. While that indicates interest from a major healthcare company, the details of the investment size, terms, and any future partnership scope were not provided in the material available for this write-up.

The Nvidia collaboration was described at a high level as work to build the foundation model for clinical conversations. Nvidia is best known for supplying accelerated computing platforms used for training and running advanced AI systems, though the specific model architecture, datasets, and deployment environment were not disclosed in the cited report.

For Lilly, an AI investment tied to clinical documentation can be interpreted as part of a broader healthcare technology shift, where life sciences companies look to improve how real-world clinical information is captured and standardized. For Abridge and Nvidia, the focus is on increasing the usefulness and sophistication of clinical AI outputs, where accuracy and workflow fit are central to adoption.

A caveat is that the report does not provide granular information on model performance, timeline, regulatory plans, privacy or security safeguards, or whether the foundation model will be used internally, offered to healthcare systems, or delivered through a specific product offering.

What to watch next is whether Abridge and its partners will outline measurable outcomes, such as documentation quality improvements, clinician satisfaction, or integration plans with electronic health record workflows. Additional disclosure on the investment and any joint go-to-market plans would also clarify how much of Lilly’s participation is tied to product deployment versus strategic support.

Why It Matters

  • If Abridge’s foundation model performs well, it could improve how clinical documentation reflects the content and context of patient conversations.
  • Partnerships with Nvidia suggest Abridge is scaling toward more general, adaptable AI rather than narrow transcription tools.
  • A strategic investment from Eli Lilly highlights continued interest from large healthcare companies in AI that touches clinical workflows and data capture.
  • Because performance, deployment plans, and safeguards were not disclosed in the report, investors and healthcare stakeholders will likely look for follow-up evidence and transparency.

Sources

Key Facts

  • Abridge said it is working with Nvidia to build a foundation model for clinical conversations.
  • The company announced a strategic investment from Eli Lilly.
  • Abridge is associated with an AI “scribe” concept that helps generate clinical notes or documentation from clinical interactions.
  • The announcements were made during a keynote referenced in a report carried by Yahoo Finance.
  • The available material does not disclose the investment amount, terms, model performance metrics, or timelines.
  • Specific details about how the foundation model will be trained, validated, or deployed were not provided in the cited report.

Healthcare Related